Serina Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Cohort one of the blinded SER-252 study showed sustained PK and exploratory motor improvements in individual patients, with Cohort two underway and SAD top-line data targeted for H1 2027. SER-252 targets a less burdensome continuous-therapy profile; a potential NDA submission is targeted for 2030, subject to data.
-
SER-252, a novel therapy for advanced Parkinson's, has completed cohort one in its phase I-B study and advanced to cohort two, with top-line data expected in early 2027. The product targets a large unmet need with a user-friendly, twice-weekly on-body system, aiming to improve adoption over current device-based therapies.
-
The meeting covered eight proposals, all of which were approved, including director elections, share increase, incentive plan amendment, and auditor ratification. No questions were raised by stockholders, and final voting results will be filed with the SEC.
-
The POZ platform enables improved delivery of small molecules, with lead program SER-252 in advanced Parkinson's showing promise for best-in-class therapy and a $1.7–$2.5 billion market opportunity. Additional programs target tardive dyskinesia and an undisclosed CNS indication, with a focus on accelerated regulatory pathways and potential partnerships.